AtomVie Global Radiopharma has opened a purpose-built radiopharmaceutical manufacturing facility in Hamilton, Ontario, Canada, with an investment of more than $160m.
The 72,300ft² site is said to be the largest single-site contract development and manufacturing organisation (CDMO) facility in North America for radiopharmaceutical development to date.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
It supports low-to-high throughput production and increases the company’s manufacturing capacity more than tenfold.
AtomVie said the building is designed to allow clients to move from early development through to commercial manufacturing, with customisable space set aside for future requirements.
Staffing is expected to grow as the site scales towards full operations. The company is targeting more than 200 employees by the end of this year.
AtomVie CEO Bruno Paquin said: “Our new purpose-built facility amplifies a proven track record of reliable global delivery and deep scientific expertise, enabling us to support the development and commercialisation of our partners’ pipelines.
“Above all, it advances our purpose of transforming patients’ lives by delivering high-quality radiopharmaceuticals to those who need them, all around the world.”
The company has worked on more than 70 clinical development and technology transfer programmes over more than a decade.
It has manufactured over 1,000 current good manufacturing practice (cGMP) batches and delivered more than 4,400 cGMP doses to patients in 28 countries across six continents.
AtomVie board of directors chairman Kevin McNeill said: “AtomVie’s new facility inauguration reflects the discipline and dedication of the AtomVie team and the confidence of the partners who have supported our growth.
“This facility continues AtomVie’s status as a leading radiopharmaceutical CDMO, now built at commercial scale to serve partners with the reliability the field requires.”
AtomVie was spun out of the Centre for Probe Development and Commercialization (CPDC), a McMaster University-based Centre of Excellence set up to build Canada’s capability in radiopharmaceutical innovation and manufacturing.
The opening event included facility tours for government representatives, clients, partners and members of the radiopharmaceutical community.
In October 2024, Radiopharm Theranostics and AtomVie entered a partnership for the development and manufacturing of 177Lu-BetaBart radioantibody to treat multiple solid tumours.
